Cancer3.AIBody Map Female Reproductive System › Gestational Trophoblastic Disease (GTD)

Gestational Trophoblastic Disease (GTD)

C58WHO Vol. 4
Female Reproductive System
Expert review of anticancer therapy
2026-09-07

The role of chemotherapy in high-risk gestational trophoblastic neoplasia.

Braga A, et al

A narrative review published in Expert Review of Anticancer Therapy concludes that multiagent chemotherapy remains the cornerstone of treatment for high-risk gestational trophoblastic neoplasia (GTN), yet delays in diagnosis, inadequate risk stratification, and inappropriate chemotherapy regimens co…

Source →
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
2026-09-03

Longitudinal AMH trajectories, ovarian reserve recovery, and fertility outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia: A real-world cohort study.

Xue W, et al

In a real-world cohort of 68 women treated with multiagent chemotherapy for high-risk gestational trophoblastic neoplasia, ovarian reserve — measured by anti-Müllerian hormone (AMH) — dropped profoundly during treatment (median 0.04 ng/mL) but recovered substantially by 6 months (median 1.26 ng/mL),…

Source →
The Journal of international medical research
2026-08-31

Variability in β-human chorionic gonadotropin concentrations following evacuation of a hydatidiform mole pregnancy: A retrospective cohort study from Vietnam.

Tran LT, et al

A retrospective cohort study of 560 Vietnamese women with molar pregnancy found that serum β-hCG levels declined significantly faster in patients who progressed to gestational trophoblastic neoplasia (GTN) than in those with relapsed molar pregnancy (-20,651.22 vs. -11,593 mUI/mL and -46,329.23 vs. …

Source →
Revista da Associacao Medica Brasileira (1992)
2026-08-28

Why do patients still die from gestational trophoblastic neoplasia? System failures beyond curability.

Braga A, et al

Despite gestational trophoblastic neoplasia (GTN) being one of the most curable malignancies known to oncology, this paper from the Revista da Associação Médica Brasileira investigates why preventable deaths continue to occur, concluding that mortality is driven by systemic healthcare failures — inc…

Source →
Frontiers in oncology
2026-08-12

Case Report: Primary non-gestational small intestinal choriocarcinoma misdiagnosed as ectopic pregnancy.

Li X, et al

A 40-year-old woman with a 2×1 cm ileal tumor was found to have primary non-gestational small intestinal choriocarcinoma after initially being misdiagnosed with ectopic pregnancy, highlighting a critical diagnostic pitfall in gynecological practice. Five cycles of FAV chemotherapy (fluorouracil, act…

Source →
Frontiers in oncology
2026-08-11

Case Report: Clinical analysis and literature review of two cases of high-grade adult-type cervical embryonal rhabdomyosarcoma.

Song W, et al

A case report published in Frontiers in Oncology describes two exceedingly rare cases of high-grade cervical embryonal rhabdomyosarcoma (ERMS) in reproductive-age women, both presenting at initial admission with stage IVB disease and regional lymph node metastasis — with Case 1 further complicated b…

Source →
International journal of fertility & sterility
2026-08-08

Effect of Intracytoplasmic Sperm Injection Alone versus ICSI and Preimplantation Genetic Screening on Pregnancy Outcomes of Patients with A History of Gestational Trophoblastic Disease: A Retrospective Study.

Chekini Z, et al

A retrospective study of 69 treatment cycles at the Royan Institute found that combining preimplantation genetic screening (PGS) with intracytoplasmic sperm injection (ICSI) does not significantly improve clinical pregnancy, miscarriage, or live birth rates compared to ICSI alone in infertile women …

Source →
JAMA oncology
2026-08-01

Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.

You B, et al

The TROPHAMET phase 1/2 trial demonstrated that avelumab combined with methotrexate achieved a 96.2% rate of successful human chorionic gonadotropin (hCG) normalization in 26 evaluable patients with low-risk gestational trophoblastic tumors (GTT), with zero relapses observed over a median follow-up …

Source →
Radiographics : a review publication of the Radiological Society of North America, Inc
2026-08-01

Imaging of Thoracic Manifestations of Obstetric and Gynecologic Disease.

Ropp AM, et al

A comprehensive review published in Radiographics describes the full spectrum of thoracic imaging manifestations arising from obstetric and gynecologic conditions, providing radiologists with a structured guide to recognizing these often-unrecognized or unexpected chest findings. The article covers …

Source →
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2026-07-30

Integration of immuno-nutritional status into International Federation of Gynecology and Obstetrics risk stratification to predict chemotherapy response and survival in gestational trophoblastic neoplasia.

Roque K, et al

A new composite model combining the Prognostic Nutritional Index (PNI) with the standard International Federation of Gynecology and Obstetrics (FIGO) risk score significantly improves the prediction of chemotherapy response in gestational trophoblastic neoplasia, achieving an area under the curve of…

Source →
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2026-07-30

Actinomycin D versus etoposide, methotrexate, actinomycin D/cyclophosphamide, and vincristine as second-line treatment in low-risk gestational trophoblastic neoplasia with primary methotrexate resistance.

Branco-Silva M, et al

A multi-agent chemotherapy regimen of etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA/CO) achieved sustained remission in 91.3% (21/23) of patients with low-risk gestational trophoblastic neoplasia who had primary resistance to first-line methotrexate, compared to only…

Source →
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
2026-07-19

FIGO staging for gestational trophoblastic neoplasia: 2026.

Ngan HY, et al

The International Federation of Gynecology and Obstetrics (FIGO) has adopted a formally updated 2026 staging and scoring system for gestational trophoblastic neoplasia (GTN), a spectrum of rare but potentially lethal and highly treatable diseases encompassing choriocarcinoma, placental site trophobl…

Source →
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia
2026-07-17

Impact of different EMA/CO treatment regimens in women with gestational trophoblastic neoplasia: brazilian multicenter retrospective cohort study.

Souza LC, et al

A Brazilian multicenter retrospective cohort study of 142 women with gestational trophoblastic neoplasia found that the modified EM/CO regimen — which omits actinomycin-D from the standard EMA/CO protocol — was associated with a higher rate of chemoresistance (27.3% vs. 14.7%) and a lower remission …

Source →
Contraception
2026-07-14

Contraceptive practices during monitoring for molar pregnancy: A mixed methods analysis.

Sheffield SM, et al

A mixed methods study of 264 patients treated for molar pregnancy at a regional gestational trophoblastic disease center found that 21.6% did not use any contraception during the critical beta-hCG monitoring period, despite guideline-based recommendations. The most commonly used methods were combine…

Source →
Health science reports
2026-06-30

Prevalence, Associated Factors, and Evaluation of Clinical and Biochemical Indices of Gestational Trophoblastic Tumors in Patients Referring to Imam Reza Hospital, Kermanshah: A Five-Year Analytical Study (2017-2022).

Mansouri N, et al

A five-year study at Imam Reza Hospital in Kermanshah, Iran, identified 382 cases of gestational trophoblastic neoplasia (GTN) among 30,133 deliveries, yielding a prevalence of 1.27%, with complete mole being the most common subtype at 56.8% and partial mole accounting for 37.7%. The most frequent c…

Source →